» Articles » PMID: 34134865

Treatment Trajectories and Barriers in Opioid Agonist Therapy for People Who Inject Drugs in Rural Puerto Rico

Overview
Specialty Psychiatry
Date 2021 Jun 17
PMID 34134865
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Research has shown medication for opioid use disorder (MOUD) to have positive effects, including reducing HIV and HCV transmission, but important barriers to access remain among people who inject drugs (PWID). Barriers include lack of social and familial support, bureaucracy, distance to treatment, poverty, and homelessness. However, we know little about how these barriers interact with each other to shape PWID's drug treatment access and retention.

Methods: We used qualitative methods with a dataset from a study conducted during 2019 with 31 active PWID residing in rural Puerto Rico. The study gathered ethnographic data and narratives about treatment trajectories to document the lived experiences of PWID as they moved in and out of treatment.

Results: Participants were at least 18 years old; 87.7% were male, the mean age was 44.1 years, and the mean age at first injection was 22 years. Participants identified homelessness, lack of proper ID or other identifying documents, and previous negative experiences with MOUD as the main barriers to treatment entry and retention. In addition, PWID's belief that MOUD simply substitutes an illegal drug for a legal one, while furthering drug dependence by chronically subjecting patients to treatment, constitutes an additional barrier to entry. Findings from this study demonstrate that MOUD barriers to access and retention compound and are severely affected by poverty and other forms of vulnerability among PWID in rural Puerto Rico.

Conclusion: Policies to increase access and retention should consider barriers not in isolation but as an assemblage of many factors.

Citing Articles

Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland.

Patel E, Grieb S, Winiker A, Ching J, Schluth C, Mehta S Harm Reduct J. 2024; 21(1):91.

PMID: 38720307 PMC: 11077846. DOI: 10.1186/s12954-024-01008-8.


Hepatitis C virus care cascade among people who inject drugs in puerto rico: Minimal HCV treatment and substantial barriers to HCV care.

Aponte-Melendez Y, Mateu-Gelabert P, Eckhardt B, Fong C, Padilla A, Trinidad-Martinez W Drug Alcohol Depend Rep. 2023; 8:100178.

PMID: 37555192 PMC: 10404601. DOI: 10.1016/j.dadr.2023.100178.


Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study.

Knight D, Nkya I, West N, Yang C, Kidorf M, Latkin C Addict Sci Clin Pract. 2023; 18(1):19.

PMID: 36973794 PMC: 10042396. DOI: 10.1186/s13722-023-00374-1.


Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma.

Austin E, Tsui J, Barry M, Tung E, Glick S, Ninburg M J Subst Abuse Treat. 2021; 137:108684.

PMID: 34911656 PMC: 10586539. DOI: 10.1016/j.jsat.2021.108684.


What Are the Correlates of Global Variations in the Prevalence of Opioid Use Disorders? An Analysis of Data From the Global Burden of Disease Study, 2019.

Rajkumar R Cureus. 2021; 13(10):e18758.

PMID: 34659934 PMC: 8514710. DOI: 10.7759/cureus.18758.

References
1.
Varas-Diaz N, Santiago-Negron S, Neilands T, Cintron-Bou F, Malave-Rivera S . Stigmatization of illicit drug use among Puerto Rican health professionals in training. P R Health Sci J. 2010; 29(2):109-16. PMC: 2877284. View

2.
Guarino H, Mateu-Gelabert P, Teubl J, Goodbody E . Young adults' opioid use trajectories: From nonmedical prescription opioid use to heroin, drug injection, drug treatment and overdose. Addict Behav. 2018; 86:118-123. PMC: 6377245. DOI: 10.1016/j.addbeh.2018.04.017. View

3.
Abadie R, Dombrowski K . "Caballo": risk environments, drug sharing and the emergence of a hepatitis C virus epidemic among people who inject drugs in Puerto Rico. Harm Reduct J. 2020; 17(1):85. PMC: 7582446. DOI: 10.1186/s12954-020-00421-z. View

4.
Cummings J, Wen H, Ko M, Druss B . Race/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiatry. 2013; 71(2):190-6. PMC: 4039494. DOI: 10.1001/jamapsychiatry.2013.3575. View

5.
Mlunde L, Sunguya B, Mbwambo J, Ubuguyu O, Yasuoka J, Jimba M . Association of opioid agonist therapy with the initiation of antiretroviral therapy - a systematic review. Int J Infect Dis. 2016; 46:27-33. DOI: 10.1016/j.ijid.2016.03.022. View